- Home
- VRAX vs NVVE Comparison
VRAX vs NVVE Comparison
Compare VRAX & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- NVVE
- Stock Information
- Founded
- VRAX 2013
- NVVE 1996
- Country
- VRAX United Kingdom
- NVVE United States
- Employees
- VRAX N/A
- NVVE N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NVVE Oil Refining/Marketing
- Sector
- VRAX Health Care
- NVVE Energy
- Exchange
- VRAX Nasdaq
- NVVE Nasdaq
- Market Cap
- VRAX 4.7M
- NVVE 5.5M
- IPO Year
- VRAX 2022
- NVVE N/A
- Fundamental
- Price
- VRAX $0.81
- NVVE $0.88
- Analyst Decision
- VRAX Strong Buy
- NVVE
- Analyst Count
- VRAX 1
- NVVE 0
- Target Price
- VRAX $3.00
- NVVE N/A
- AVG Volume (30 Days)
- VRAX 37.2K
- NVVE 2.8M
- Earning Date
- VRAX 02-05-2025
- NVVE 08-12-2025
- Dividend Yield
- VRAX N/A
- NVVE N/A
- EPS Growth
- VRAX N/A
- NVVE N/A
- EPS
- VRAX N/A
- NVVE N/A
- Revenue
- VRAX $84,872.00
- NVVE $5,440,777.00
- Revenue This Year
- VRAX $5,169.18
- NVVE $892.33
- Revenue Next Year
- VRAX $66.97
- NVVE N/A
- P/E Ratio
- VRAX N/A
- NVVE N/A
- Revenue Growth
- VRAX 7.03
- NVVE N/A
- 52 Week Low
- VRAX $0.75
- NVVE $0.82
- 52 Week High
- VRAX $9.00
- NVVE $8.80
- Technical
- Relative Strength Index (RSI)
- VRAX 31.75
- NVVE 42.76
- Support Level
- VRAX $0.75
- NVVE $1.22
- Resistance Level
- VRAX $0.85
- NVVE $1.54
- Average True Range (ATR)
- VRAX 0.07
- NVVE 0.16
- MACD
- VRAX -0.01
- NVVE -0.04
- Stochastic Oscillator
- VRAX 6.57
- NVVE 9.73
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.